Cochrane · systematic review · CD008314
Topiramate for neuropathic pain and fibromyalgia in adults
Wiffen, PJ, Derry, S, Lunn, MPT, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
2
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 3 · 42.9%Very low 0 · 0%Low 0 · 0%Moderate 2 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Topiramate 200 to 400 mg versus placebo for neuropathic pain
Population: neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 50% reduction in pain or equivalent Topiramate 200 to 400 mg vs placebo | no estimate extracted | 1 study · 317 participants | Ungraded |
"Moderate" benefit At least 30% reduction in pain Topiramate 200 to 400 mg vs placebo | no estimate extracted | 1 study · 317 participants | Ungraded |
Proportion below 30/100 mm on VAS Topiramate 200 to 400 mg vs placebo | no estimate extracted | NR | No studies |
Patient Global Impression of Change much or very much improved Topiramate 200 to 400 mg vs placebo | no estimate extracted | 2 studies · 399 participants | Ungraded |
Adverse event withdrawals Topiramate 200 to 400 mg vs placebo | RR 3.4 [4.3, 7.1] | 1038 participants | Moderate |
Serious adverse events Topiramate 200 to 400 mg vs placebo | RR 0.9 [0.6, 1.3] | 1586 participants | Moderate |
Death Topiramate 200 to 400 mg vs placebo | no estimate extracted | NR | No studies |